SE9603408D0 - Medical use - Google Patents

Medical use

Info

Publication number
SE9603408D0
SE9603408D0 SE9603408A SE9603408A SE9603408D0 SE 9603408 D0 SE9603408 D0 SE 9603408D0 SE 9603408 A SE9603408 A SE 9603408A SE 9603408 A SE9603408 A SE 9603408A SE 9603408 D0 SE9603408 D0 SE 9603408D0
Authority
SE
Sweden
Prior art keywords
medical use
gastro
inhibition
treatment
receptor agonists
Prior art date
Application number
SE9603408A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Lehmann
Paul Andrews
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9603408(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9603408A priority Critical patent/SE9603408D0/xx
Publication of SE9603408D0 publication Critical patent/SE9603408D0/xx
Priority to ARP970104051A priority patent/AR007747A1/es
Priority to ZA9707969A priority patent/ZA977969B/xx
Priority to TW086113275A priority patent/TW548104B/zh
Priority to IDP973172A priority patent/ID19621A/id
Priority to AT97942346T priority patent/ATE249212T1/de
Priority to KR1020057018539A priority patent/KR100568659B1/ko
Priority to PL97332497A priority patent/PL190028B1/pl
Priority to DE69724809T priority patent/DE69724809T2/de
Priority to NZ334495A priority patent/NZ334495A/xx
Priority to RU99107969/14A priority patent/RU2199316C2/ru
Priority to US08/952,400 priority patent/US6117908A/en
Priority to ES03013667T priority patent/ES2268227T3/es
Priority to DK03013667T priority patent/DK1344524T3/da
Priority to SK305-99A priority patent/SK285744B6/sk
Priority to ES97942346T priority patent/ES2206749T3/es
Priority to EEP199900095A priority patent/EE03952B1/xx
Priority to CA002265615A priority patent/CA2265615C/en
Priority to NZ504244A priority patent/NZ504244A/xx
Priority to CZ0093099A priority patent/CZ299997B6/cs
Priority to EP97942346A priority patent/EP0936906B1/en
Priority to IL12896197A priority patent/IL128961A/en
Priority to HK00101114.9A priority patent/HK1022100B/en
Priority to HU9903825A priority patent/HU224968B1/hu
Priority to PT97942346T priority patent/PT936906E/pt
Priority to TR1999/00591T priority patent/TR199900591T2/xx
Priority to UA99031298A priority patent/UA61081C2/uk
Priority to SI9730594T priority patent/SI0936906T1/xx
Priority to DK97942346T priority patent/DK0936906T3/da
Priority to DE69736445T priority patent/DE69736445T2/de
Priority to PT03013667T priority patent/PT1344524E/pt
Priority to EP03013667A priority patent/EP1344524B1/en
Priority to PCT/SE1997/001555 priority patent/WO1998011885A1/en
Priority to BR9711400A priority patent/BR9711400A/pt
Priority to AU44064/97A priority patent/AU714370B2/en
Priority to AT03013667T priority patent/ATE334700T1/de
Priority to SI9730749T priority patent/SI1344524T1/sl
Priority to KR1019997002239A priority patent/KR100553294B1/ko
Priority to CN97199600A priority patent/CN1117560C/zh
Priority to JP51458198A priority patent/JP4098832B2/ja
Priority to MYPI97004296A priority patent/MY122020A/en
Priority to SA97180522A priority patent/SA97180522B1/ar
Priority to IS5001A priority patent/IS2329B/is
Priority to NO19991287A priority patent/NO326837B1/no
Priority to US09/658,242 priority patent/US6664069B1/en
Priority to HK03109347.8A priority patent/HK1057004B/en
Priority to IS8623A priority patent/IS2538B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
SE9603408A 1996-09-18 1996-09-18 Medical use SE9603408D0 (sv)

Priority Applications (47)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use
ARP970104051A AR007747A1 (es) 1996-09-18 1997-09-04 Inhibidores del reflujo
ZA9707969A ZA977969B (en) 1996-09-18 1997-09-04 Reflux inhibitors.
TW086113275A TW548104B (en) 1996-09-18 1997-09-12 Pharmaceutical compositions for inhibiting transient lower esophageal sphincter relaxations
IDP973172A ID19621A (id) 1996-09-18 1997-09-12 Penghambat refluks
AT97942346T ATE249212T1 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
KR1020057018539A KR100568659B1 (ko) 1996-09-18 1997-09-15 역류 억제제
PL97332497A PL190028B1 (pl) 1996-09-18 1997-09-15 Zastosowanie agonisty receptora GABA
DE69724809T DE69724809T2 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
NZ334495A NZ334495A (en) 1996-09-18 1997-09-15 Use of GABA receptor agonists such as substituted amino propyl acid derivatives to inhibit transient lower esophageal sphincter relaxations
RU99107969/14A RU2199316C2 (ru) 1996-09-18 1997-09-15 Вещества, подавляющие рефлюкс
US08/952,400 US6117908A (en) 1996-09-18 1997-09-15 Use of GABAB receptor agonists as reflux inhibitors
ES03013667T ES2268227T3 (es) 1996-09-18 1997-09-15 Inhibidores del reflujo.
DK03013667T DK1344524T3 (da) 1996-09-18 1997-09-15 Refluksinhibitorer
SK305-99A SK285744B6 (sk) 1996-09-18 1997-09-15 Použitie agonistov receptora GABAB ako inhibítorov refluxu
ES97942346T ES2206749T3 (es) 1996-09-18 1997-09-15 Inhibidores del reflujo.
EEP199900095A EE03952B1 (et) 1996-09-18 1997-09-15 Tagasivoolu inhibiitorid
CA002265615A CA2265615C (en) 1996-09-18 1997-09-15 Reflux inhibitors
NZ504244A NZ504244A (en) 1996-09-18 1997-09-15 Method for the screening of inhibitors of transient lower esophageal sphincter relaxations using a GABAb receptor
CZ0093099A CZ299997B6 (cs) 1996-09-18 1997-09-15 Inhibitory refluxu
EP97942346A EP0936906B1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
IL12896197A IL128961A (en) 1996-09-18 1997-09-15 Pharmaceutical preparations containing GABAß receptor agonists and their use as reuptake inhibitors
HK00101114.9A HK1022100B (en) 1996-09-18 1997-09-15 Reflux inhibitors
HU9903825A HU224968B1 (en) 1996-09-18 1997-09-15 Use of gabab receptor agonists for production of anti reflux pharmaceutical compositions
PT97942346T PT936906E (pt) 1996-09-18 1997-09-15 Inibidores do refluxo
TR1999/00591T TR199900591T2 (xx) 1996-09-18 1997-09-15 Geri ak�� �nleyicileri.
UA99031298A UA61081C2 (uk) 1996-09-18 1997-09-15 Активний компонент для придушення тимчасових релаксацій нижнього сфінктера, спосіб такого придушення та спосіб скринінгу сполук
SI9730594T SI0936906T1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
DK97942346T DK0936906T3 (da) 1996-09-18 1997-09-15 Refluxhæmmere
DE69736445T DE69736445T2 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
PT03013667T PT1344524E (pt) 1996-09-18 1997-09-15 Inibidores de refluxo
EP03013667A EP1344524B1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
PCT/SE1997/001555 WO1998011885A1 (en) 1996-09-18 1997-09-15 Reflux inhibitors
BR9711400A BR9711400A (pt) 1996-09-18 1997-09-15 Uso de um agonista receptor gabab ou de um sal farmaceuticamente aceit vel ou de um isÄmero Äptico do dito agonista receptor gabab e processos para a inibi-Æo de relaxamentos do esfincter esofagiano transiente inferior e para a sele-Æo de composto que sÆo inibidores de relaxamentos de esfincter esofagiano transiente inferior
AU44064/97A AU714370B2 (en) 1996-09-18 1997-09-15 Reflux inhibitors
AT03013667T ATE334700T1 (de) 1996-09-18 1997-09-15 Refluxinhibitoren
SI9730749T SI1344524T1 (sl) 1996-09-18 1997-09-15 Inhibitorji refluksa
KR1019997002239A KR100553294B1 (ko) 1996-09-18 1997-09-15 역류 억제제
CN97199600A CN1117560C (zh) 1996-09-18 1997-09-15 反流抑制剂
JP51458198A JP4098832B2 (ja) 1996-09-18 1997-09-15 逆流抑制剤
MYPI97004296A MY122020A (en) 1996-09-18 1997-09-16 Use of gabab receptor agonists as reflux inhibitors
SA97180522A SA97180522B1 (ar) 1996-09-18 1997-10-27 مثبطات الترجيع reflux
IS5001A IS2329B (is) 1996-09-18 1999-03-15 Bakflæðishemlar
NO19991287A NO326837B1 (no) 1996-09-18 1999-03-17 Anvendelse av GABAB-reseptoragonister for inhibering av transiente relaksjoner av nedre osofagfinkter
US09/658,242 US6664069B1 (en) 1996-09-18 2000-09-08 Use of GABAB receptor agonists in the screening of compounds which are reflux inhibitors
HK03109347.8A HK1057004B (en) 1996-09-18 2003-12-23 Reflux inhibitors
IS8623A IS2538B (is) 1996-09-18 2007-03-19 Bakflæðishemlar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Publications (1)

Publication Number Publication Date
SE9603408D0 true SE9603408D0 (sv) 1996-09-18

Family

ID=20403936

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Country Status (34)

Country Link
US (2) US6117908A (pl)
EP (2) EP1344524B1 (pl)
JP (1) JP4098832B2 (pl)
KR (2) KR100553294B1 (pl)
CN (1) CN1117560C (pl)
AR (1) AR007747A1 (pl)
AT (2) ATE334700T1 (pl)
AU (1) AU714370B2 (pl)
BR (1) BR9711400A (pl)
CA (1) CA2265615C (pl)
CZ (1) CZ299997B6 (pl)
DE (2) DE69724809T2 (pl)
DK (2) DK1344524T3 (pl)
EE (1) EE03952B1 (pl)
ES (2) ES2268227T3 (pl)
HU (1) HU224968B1 (pl)
ID (1) ID19621A (pl)
IL (1) IL128961A (pl)
IS (2) IS2329B (pl)
MY (1) MY122020A (pl)
NO (1) NO326837B1 (pl)
NZ (2) NZ504244A (pl)
PL (1) PL190028B1 (pl)
PT (2) PT936906E (pl)
RU (1) RU2199316C2 (pl)
SA (1) SA97180522B1 (pl)
SE (1) SE9603408D0 (pl)
SI (2) SI1344524T1 (pl)
SK (1) SK285744B6 (pl)
TR (1) TR199900591T2 (pl)
TW (1) TW548104B (pl)
UA (1) UA61081C2 (pl)
WO (1) WO1998011885A1 (pl)
ZA (1) ZA977969B (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
JP2004532259A (ja) * 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
AR033779A1 (es) 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
BR0317253A (pt) * 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
PL1660440T3 (pl) * 2003-08-20 2012-07-31 Xenoport Inc Proleki acyloksyalkilokarbaminianowe, sposoby syntezy i zastosowanie
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
WO2005026208A2 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric gabab receptor
PT1677767E (pt) * 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
GB0327186D0 (en) * 2003-11-21 2003-12-24 Novartis Ag Organic compounds
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
AU2006327313A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic GABA-B modulators
JP2009521428A (ja) * 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ 胃腸疾患治療用のイミダゾール誘導体
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
WO2007073299A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazoles as gaba-b receptor modulators
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
TR201910825T4 (tr) * 2006-12-22 2019-08-21 Ironwood Pharmaceuticals Inc Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler
US20080206332A1 (en) * 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
CA2682301A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
EP2217245A4 (en) * 2007-07-25 2011-01-12 Astrazeneca Ab USE OF (3-AMINO-2-FLUOROPROPYL) -PHOSPHIC ACID FOR THE TREATMENT OF NERD
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) * 2008-03-20 2015-03-31 Burt Shulman Compound and method for treatment of gastroesophageal reflux
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
NZ594648A (en) 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) * 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2013180796A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
US12161695B2 (en) * 2018-02-22 2024-12-10 Diamyd Medical Ab GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
AU5106790A (en) * 1989-02-03 1990-09-05 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
EP0556880A3 (en) * 1992-01-22 1993-10-27 Glaxo Group Limited Medical use for atypical beta-adrenoceptor agonists
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
MY122020A (en) 2006-03-31
CN1237105A (zh) 1999-12-01
CZ299997B6 (cs) 2009-01-14
KR20000036185A (ko) 2000-06-26
PL332497A1 (en) 1999-09-13
HK1057004A1 (en) 2004-03-12
EP1344524B1 (en) 2006-08-02
SA97180522B1 (ar) 2006-04-04
DE69724809D1 (de) 2003-10-16
NO991287D0 (no) 1999-03-17
UA61081C2 (uk) 2003-11-17
JP2001501604A (ja) 2001-02-06
DE69736445T2 (de) 2007-03-15
AU714370B2 (en) 1999-12-23
RU2199316C2 (ru) 2003-02-27
TW548104B (en) 2003-08-21
CZ93099A3 (cs) 1999-09-15
IL128961A0 (en) 2000-02-17
NO326837B1 (no) 2009-02-23
PT1344524E (pt) 2006-11-30
HUP9903825A2 (hu) 2001-05-28
BR9711400A (pt) 1999-08-17
ES2206749T3 (es) 2004-05-16
JP4098832B2 (ja) 2008-06-11
DE69736445D1 (de) 2006-09-14
US6664069B1 (en) 2003-12-16
NO991287L (no) 1999-03-17
ATE334700T1 (de) 2006-08-15
SI1344524T1 (sl) 2006-12-31
HUP9903825A3 (en) 2001-06-28
IL128961A (en) 2004-08-31
SI0936906T1 (en) 2004-02-29
EE9900095A (et) 1999-10-15
DE69724809T2 (de) 2004-07-15
ZA977969B (en) 1998-03-18
SK285744B6 (sk) 2007-07-06
KR100553294B1 (ko) 2006-02-22
EP1344524A1 (en) 2003-09-17
US6117908A (en) 2000-09-12
ATE249212T1 (de) 2003-09-15
AR007747A1 (es) 1999-11-10
NZ334495A (en) 2000-09-29
HK1022100A1 (en) 2000-07-28
TR199900591T2 (xx) 1999-07-21
AU4406497A (en) 1998-04-14
IS8623A (is) 2007-03-19
PL190028B1 (pl) 2005-10-31
KR100568659B1 (ko) 2006-04-07
CA2265615A1 (en) 1998-03-26
KR20050101237A (ko) 2005-10-20
IS2538B (is) 2009-09-15
EP0936906A1 (en) 1999-08-25
IS2329B (is) 2008-01-15
EE03952B1 (et) 2003-02-17
PT936906E (pt) 2003-12-31
DK0936906T3 (da) 2003-11-24
ES2268227T3 (es) 2007-03-16
ID19621A (id) 1998-07-23
NZ504244A (en) 2000-09-29
HU224968B1 (en) 2006-04-28
SK30599A3 (en) 2000-01-18
EP0936906B1 (en) 2003-09-10
CN1117560C (zh) 2003-08-13
DK1344524T3 (da) 2006-10-30
IS5001A (is) 1999-03-15
WO1998011885A1 (en) 1998-03-26
CA2265615C (en) 2007-01-30

Similar Documents

Publication Publication Date Title
SE9603408D0 (sv) Medical use
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE59203983D1 (de) Endoskopische Koagulationsfasszange.
DE69925854D1 (de) Endoskopische bipolare elektrochirurgische zange
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
BR9809185A (pt) Diidropiranos fundidos
ATE76069T1 (de) 5-nitrobenzo(de>isochinolin-1,3-dione, ihre herstellung und verwendung.
BR9813540A (pt) Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
TR199902257T2 (xx) Tetrahidropirido bile�ikleri
DE60013947D1 (de) (Poly)thia-alkin-Verbindungen und ihre Derivate, diese enthaltende Zusammensetzungen und ihre Anwendung
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DE50101861D1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
BR9708595A (pt) Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
DK1121108T3 (da) Ny terapeutisk anvendelse af forbindelser med beta-3-agonistaktivitet
TR200101729T2 (tr) IL-5 engelleyici 6-azaurasil türevleri